Veradermics rises 12.4% after positive Phase 3 topline results

What happened

Veradermics (MANE) rose 12.4% on October 19, 2026, after the company announced positive topline results from Part A of Study 304, its randomized, double-blind, placebo-controlled Phase 3 trial evaluating VDPHL01. The company said the extended-release oral minoxidil tablet for men with mild-to-moderate pattern hair loss produced early, consistent, and strong hair growth and that Study 304 met all endpoints reported in Part A. Veradermics scheduled an investor conference call and webcast to review the results on October 19, 2026, at 8:00 am ET. The news was reported by Business Wire and Seeking Alpha.

How big was the move

The stock rose 12.4% and closed the session at $122.28 after opening 6.0% above the previous close. Trading volume ran 1.6 times its 20-day average, and the move was 3.1 times a typical daily move for this stock. By contrast, the S&P 500 rose 0.4% and the healthcare sector median rose 1.0%, leaving the stock 11.4 percentage points better than the sector median.

Those figures point to a large, mostly company-specific move that came after the company released its Part A topline results and ahead of the scheduled call. The stock’s outperformance versus both the market and its sector, combined with elevated volume, suggests investors were reacting directly to the clinical news.

The technical picture

The stock finished the session 4.1% above its 20-day moving average and 11.8% above its 50-day moving average. The Relative Strength Index (14 days) was 56, a neutral reading between 30 and 70. Over one month the stock had risen 14.5% and over three months it had risen 11.7%.

Volatility was 63% annualized over 60 days, consistent with a pattern of pronounced moves around clinical developments. Those technicals show recent gains alongside elevated variability, a mix that investors typically weigh when momentum follows binary trial updates.

Fundamentals and valuation

For the four quarters through June 30, 2026, Veradermics reported revenue of $0 and a return on invested capital of 12.6%. The balance sheet showed net cash of $318.9 million, and the company’s share count over one year decreased by 79.9%. Market value on the session was $4.55 billion.

Valuation metrics included a free-cash-flow yield of 1.7%. PromtFinance scores ranked the company 62 for Value (Neutral), 14 for Quality (Very weak), 43 for Revisions (Weak), and 78 for Stability (Positive). Those scores frame a company with limited revenue, a strong cash position, and quality metrics the ranking treats as weak versus peers.

Taken together, the fundamentals show a biotech enterprise that has not yet generated product revenue but holds a notable cash cushion. The steep reduction in share count over the past year is a material factor for per-share metrics and market capitalization.

Earnings and analyst expectations

Veradermics last reported on August 11, 2026, when it posted earnings per share of $-0.58 against $-0.65 expected, 10.4% above estimates. The company had one consecutive quarter beating estimates. The average surprise over the last four reports was 38.3% below estimates, and the typical two-day reaction after recent reports was that the stock fell 3.1%.

Four analysts cover the stock and the consensus rating is Buy. The consensus price target is $162.67, 33.0% above the session closing price.

What to watch

• November 10, 2026: next scheduled earnings report.
• October 19, 2026, at 8:00 am ET: investor conference call and webcast to review Study 304 Part A topline results.
• Market value of $4.55 billion and closing price of $122.28 as reference points for analyst coverage.
• Share count over one year decreased by 79.9% and net cash of $318.9 million on the balance sheet.